Summary. Ten feral mares free-roaming in Maryland, USA, were inoculated with porcine zonae pellucidae (PZP)

No abstract

Abstract. In North America, dense populations of white-tailed deer (Odocoileus virginianus) in suburbs, cities and towns have stimulated a search for new population-management tools. Most research on deer contraception has focused on the safety and efficacy of immunocontraceptive vaccines, but few studies have examined population-level effects. We report here results from two long-term studies of population effects of the porcine zona pellucida (PZP) immunocontraceptive vaccine, at the National Institute of Standards and Technology (NIST), Gaithersburg, Maryland, USA, and at Fire Island National Seashore (FIIS), New York, USA. Annual population change at NIST was strongly correlated with population fertility (r P = 0.82, P = 0.001); when population fertility at NIST dropped below 0.40 fawns per female, the population declined. Contraceptive treatments at NIST were associated with a 27% decline in population between 1997 and 2002, and fluctuated thereafter with the effectiveness of contraceptive treatments. In the most intensively treated segment of FIIS, deer population density declined by~58% between 1997 and 2006. These studies demonstrate that, in principle, contraception can significantly reduce population size. Its usefulness as a management tool will depend on vaccine effectiveness, accessibility of deer for treatment, and site-specific birth, death, immigration, and emigration rates.

No abstract

Successful immunocontraception of wildlife relying on repeated access to individuals for boosters has highlighted the need to incorporate primer and booster immunisations into one injection. We have investigated use of controlled-release polymers (lactide-glycolide) in small pellets to provide delayed in vivo delivery of booster porcine zona pellucida (PZP) antigen and adjuvant. This report reviews pellet-making methodology, in vitro testing of controlled-release pellets and in vivo effects of controlled-release PZP vaccine. We assessed 3 different manufacturing approaches for producing reliable, cost-effective pellets: (1) polymer melting and extrusion; (2) solvent evaporation from polymer solution; and (3) punch and die polymer moulding. In vitro testing of release patterns of controlled-release formulations, towards development of a 3-year duration vaccine, provided estimates for in vivo use of pellet preparations. These in vitro studies demonstrated protein release delay up to 22 months using 100% l-lactide or polycaprolactone polymers. For in vivo tests, pellets (1-, 3-, and 12-month release delay) serving as boosters were administered intramuscularly with PZP/adjuvant liquid primer to wild horses (Equus caballus), white-tailed deer (Odocoileus virginanus) and African elephants (Loxodonta africana). Horse field studies assessed fertility via offspring counts and/or faecal-hormone pregnancy testing. Treatment decreased fertility 5.3-9.3-fold in Year 1 and 3.6-fold in Year 2. In preliminary testing in deer, offspring counts revealed treatment-associated fertility reduction of 7.1-fold Year 1 and 3.3-fold Year 2. In elephants, treatment elevated anti-PZP titres 4.5-6.9-fold from pretreatment (no fertility data).